SARS-CoV-2 and COVID-19: Plasma Supply and IG Replacement Therapy to Protect Immunodeficient Patients
Can anti-SARS-CoV-2 antibodies in the plasma supply protect against COVID infection in
immunodeficient patients? Research suggests otherwise.
Plasma’s Pivotal Role in Cancer Therapy
Known as liquid gold, human plasma is proving to be a valuable ally in the fight against cancer.
Therapeutic Plasma Exchange: A Promising New Treatment for Sepsis and Septic Shock
Therapeutic plasma exchange may improve outcomes for patients diagnosed with sepsis or septic shock, but funding is needed to conduct needed clinical trials.
Grifols Receives $21M to Study Parkinson’s Plasma Samples
Grifols has received $21 million from the Michael J. Fox Foundation to fund a pilot study analyzing the company’s repository of longitudinal Parkinson’s disease (PD) plasma samples in hopes of developing an early-warning system for the emergence of PD.
The Expanding Role of Immune Globulin Treatment in Diseases: Utilization and Growth
New research showing the therapeutic benefit of immune globulin for treating a variety of autoimmune diseases is contributing to market growth of this essential medicine.
Platelet-Rich Plasma Therapy: The Future of Healing?
The effectiveness of this controversial therapy in treating musculoskeletal disorders and other arthritic conditions is uncertain due to mixed results. Nevertheless, the PRP industry is booming.
Coming Soon: Dried Plasma for Hemorrhagic Trauma in the Prehospital Setting
It is now well-established that prehospital transfusion of plasma, with its balanced mix of coagulation proteins, counters the hemodilution and progressive derangement of hemostatic mechanisms caused by crystalloid-based resuscitation, improving the changes of survival in severely bleed trauma victims.
The Current Challenge of Immune Globulin Access
Understanding the factors contributing to the current shortage of immune globulin could help to address a crisis that threatens dire consequences for patients.
In Case of a Shortage: Strategies to Conserve the Immune Globulin Supply
What can be done in the event of a severe shortage of IG products, whose production is entirely reliant on a continuous supply of IgG-rich plasma donated at more than 800 dedicated U.S. collection facilities?
The Promise of COVID-19 Hyperimmune Immune Globulin Therapy
As of this writing, NIAID and industry collaborators are also finalizing the design of a large-scale trial to assess whether COVID-Ig can reduce the rate of hospitalization and other medical encounters in earlier-stage COVID-19 patients exhibiting mild to moderate symptoms.